OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 6.27 EUR -2.64% Market Closed
Market Cap: 137.6m EUR

Net Margin
OSE Immunotherapeutics SA

55.2%
Current
-279%
Average
-7.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
55.2%
=
Net Income
46m
/
Revenue
83.4m

Net Margin Across Competitors

OSE Immunotherapeutics SA
Glance View

Market Cap
136.5m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
7.93 EUR
Undervaluation 21%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
55.2%
=
Net Income
46m
/
Revenue
83.4m
What is the Net Margin of OSE Immunotherapeutics SA?

Based on OSE Immunotherapeutics SA's most recent financial statements, the company has Net Margin of 55.2%.

Back to Top